Acquisition - August 16, 2016
Mylan completes acquisition of Meda
Earlier this month Mylan announced that it has completed the settlement of its recommended public offer to the shareholders of Meda Aktiebolag to tender all their shares in Meda to Mylan. The offer was accepted by shareholders holding approximately 94% of the total number of outstanding shares and votes in Meda, as of July 29, 2016. […]
Acquisition - February 11, 2016
Mylan to buy Meda fo $7.2 billion
The generic drugmaker Mylan said it would acquire Swedish drugmaker Meda in a $7.2 billion cash-and-stock deal. It is Mylan’s third attempt to buy the company. The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo. Mylan’s stock fell about 8 pct in extended trading, after it announced the […]
Regulatory compliance - December 8, 2014
Meda, Cipla Suing Apotex
Meda Pharmaceuticals Inc. and Cipla Ltd. announced recently that they sued Apotex Inc. and Apotex Corp. in U.S. Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray in response to Apotex’s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA), and […]
Companies - December 5, 2014
Meda to Stop Making Penicillin in Sweden
Meda, one of Recipharm’s customers, has today advised that it will transfer supply of its mainly Swedish penicillin products and manufacture offshore with other suppliers. The manufacturing contract with Recipharm Strängnäs will be terminated on Dec. 31, 2015. This business accounts for approximately 2% of Recipharm’s current sales. Recipharm currently employs 60 employees in Strängnäs and unfortunately the […]
Acquisition - October 13, 2014
Meda launches rights issue to help pay for Rottapharm
As part of the financing of the acquisition of Rottapharm, Meda’s Board of Directors has resolved to launch a rights issue of approximately SEK 2.0 billion. On 31 July 2014, Meda announced entering into an agreement to acquire the Italian specialty pharma company Rottapharm S.p.A. Completion of the transaction was subject to certain conditions, including […]
Pharma Business - September 5, 2014
Meda divests US unit
Meda has signed an agreement to divest the manufacturing unit in Lakewood, New Jersey. The manufacturing unit will be divested to the contract manufacturer DPT. According to Meda the manufacturing facility is dedicated to global supply of the product MUSE. As part of the agreement Meda has entered into a long term supply agreement with DPT […]
